PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16007523-2 2005 Like erythromycin, it may interact with other drugs by interfering with metabolism by cytochrome P450 enzymes and with the P-glycoprotein transporter system. Erythromycin 5-17 ATP binding cassette subfamily B member 1 Homo sapiens 123-137 18027988-4 2007 RESULTS: All macrolides inhibited P-glycoprotein-mediated digoxin transport, with concentrations producing 50% inhibition (IC(50)) values of 1.8, 4.1, 15.4, 21.8 and 22.7 micromol/L for telithromycin, clarithromycin, roxithromycin, azithromycin and erythromycin, respectively. Erythromycin 249-261 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 15543082-4 2004 Transport of erythromycin was then studied with P-gp saturable concentrations of fluoroquinolones. Erythromycin 13-25 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 15543082-1 2004 The purpose of this study was to determine the interactions of erythromycin and various fluoroquinolones with P-glycoprotein (P-gp) and in turn assess their effects on transport kinetics across a model cell monolayer. Erythromycin 63-75 ATP binding cassette subfamily B member 1 Homo sapiens 110-124 12426516-13 2002 The erythromycin-rifampin interaction cannot be attributed to CYP3A4 induction alone and probably also reflected intestinal P-glycoprotein induction. Erythromycin 4-16 ATP binding cassette subfamily B member 1 Homo sapiens 124-138 15543082-1 2004 The purpose of this study was to determine the interactions of erythromycin and various fluoroquinolones with P-glycoprotein (P-gp) and in turn assess their effects on transport kinetics across a model cell monolayer. Erythromycin 63-75 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 15621665-3 2004 In the presence of digoxin, secretory transport of vinblastine and erythromycin, substrates for both Pgp and cytochrome P450 3A4 (CYP3A4), was significantly reduced, whereas absorptive transport was unaffected. Erythromycin 67-79 ATP binding cassette subfamily B member 1 Homo sapiens 101-104 12909563-0 2003 Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test. Erythromycin 87-99 ATP binding cassette subfamily B member 1 Homo sapiens 49-52 12909563-8 2003 It is concluded that the combined oral and intravenous erythromycin breath and urine test is a reliable and noninvasive test to measure phenotypic intestinal and hepatic CYP3A4 and PGP activity and may be a promising tool for prediction of drug interactions and dose adjustment of many pharmacotherapeutics in clinical practice, e.g., immunosuppressive agents after renal transplantation. Erythromycin 55-67 ATP binding cassette subfamily B member 1 Homo sapiens 181-184 12426516-0 2002 Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Erythromycin 79-91 ATP binding cassette subfamily B member 1 Homo sapiens 24-38 11724091-8 2001 Both drugs are potent inhibitors of CYP3A4 and of P-glycoprotein; this may be the basis for the pharmacokinetic interaction between erythromycin and verapamil. Erythromycin 132-144 ATP binding cassette subfamily B member 1 Homo sapiens 50-64 10783825-0 2000 P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Erythromycin 25-37 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 10783825-1 2000 OBJECTIVE: Increased bioavailability of the P-glycoprotein (Pgp) substrates digoxin and cyclosporin due to erythromycin has been observed in vivo. Erythromycin 107-119 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 10783825-1 2000 OBJECTIVE: Increased bioavailability of the P-glycoprotein (Pgp) substrates digoxin and cyclosporin due to erythromycin has been observed in vivo. Erythromycin 107-119 ATP binding cassette subfamily B member 1 Homo sapiens 60-63 10783825-11 2000 CONCLUSION: We suggest that the increase in oral bioavailability of talinolol after concomitant erythromycin is caused by increased intestinal net absorption due to Pgp inhibition by erythromycin. Erythromycin 96-108 ATP binding cassette subfamily B member 1 Homo sapiens 165-168 10783825-11 2000 CONCLUSION: We suggest that the increase in oral bioavailability of talinolol after concomitant erythromycin is caused by increased intestinal net absorption due to Pgp inhibition by erythromycin. Erythromycin 183-195 ATP binding cassette subfamily B member 1 Homo sapiens 165-168 9822896-0 1998 Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Erythromycin 49-61 ATP binding cassette subfamily B member 1 Homo sapiens 17-31 9822896-3 1998 The basal-to-apical transport of rhodamine 123, a P-glycoprotein substrate, was inhibited by erythromycin, midazolam and ketoconazole, as well as by P-glycoprotein inhibitors such as verapamil. Erythromycin 93-105 ATP binding cassette subfamily B member 1 Homo sapiens 50-64 9822896-7 1998 In conclusion, erythromycin, midazolam and ketoconazole could interact with P-glycoprotein-mediated transport, and P-glycoprotein could be, at least in part, involved in the transport of erythromycin, but not of midazolam and ketoconazole, in the intestinal epithelia. Erythromycin 15-27 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 9822896-7 1998 In conclusion, erythromycin, midazolam and ketoconazole could interact with P-glycoprotein-mediated transport, and P-glycoprotein could be, at least in part, involved in the transport of erythromycin, but not of midazolam and ketoconazole, in the intestinal epithelia. Erythromycin 187-199 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 9822896-7 1998 In conclusion, erythromycin, midazolam and ketoconazole could interact with P-glycoprotein-mediated transport, and P-glycoprotein could be, at least in part, involved in the transport of erythromycin, but not of midazolam and ketoconazole, in the intestinal epithelia. Erythromycin 187-199 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 20977453-6 2010 MDR1 expression attenuated KCNA5 block by erythromycin (an MDR1 substrate). Erythromycin 42-54 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 20977453-6 2010 MDR1 expression attenuated KCNA5 block by erythromycin (an MDR1 substrate). Erythromycin 42-54 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 20621639-1 2010 In this study five macrolide antibiotics (azithromycin, erythromycin, clarithromycin, roxithromycin and telithromycin) were compared based on their ability to interact with human MDR1 (ABCB1, P-glycoprotein), studied from two main aspects: by determining the influence of macrolide antibiotics on MDR1 function, as well as the influence of MDR1 on macrolide accumulation in MES-SA/Dx5 cells overexpressing human MDR1. Erythromycin 56-68 ATP binding cassette subfamily B member 1 Homo sapiens 179-183 20023051-9 2010 The results also suggest that inhibition of hepatic P-gp is involved in the erythromycin-ximelagatran interaction seen in clinical studies. Erythromycin 76-88 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 20724802-8 2010 Using paclitaxel as a known P-gp substrate, erythromycin demonstrated only partial P-gp inhibitory capacity, maintaining an efflux ratio over 100. Erythromycin 44-56 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 20724802-8 2010 Using paclitaxel as a known P-gp substrate, erythromycin demonstrated only partial P-gp inhibitory capacity, maintaining an efflux ratio over 100. Erythromycin 44-56 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 18703021-7 2008 A number of Pgp substrates (quinidine, amprenavir, irinotecan, topotecan, atorvastatin and erythromycin) induced net digoxin secretion, as did the non-Pgp substrate artemisinin. Erythromycin 91-103 ATP binding cassette subfamily B member 1 Homo sapiens 12-15 18928592-9 2008 Both of garlicin and erythromycin alone could down-regulate the expression of mdr1 and P-gp of K562/A02 and elevate the intracellular concentrations of ADM in K562/A02 cells. Erythromycin 21-33 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 20621639-4 2010 Expression of MDR1 on cells decreased macrolide accumulation in cells from 2- to 80-fold with the most pronounced change observed for azithromycin and erythromycin. Erythromycin 151-163 ATP binding cassette subfamily B member 1 Homo sapiens 14-18